This will likely become the landmark study about the overall rate of neuropsychiatric side effects with this class of medicines over the next several years.
Research shows the boosted integrase inhibitor-based fixed-dose combination Stribild can be safely crushed without affecting pharmacokinetics.
Stribild (Elvitegravir, Cobicistat, Emtrictiabine, Tenofovir Disoproxil Fumarate) Tablet Label Revised to Expand the Patient Population
Among a number of changes to Stribild's label, it has been revised to expand the patient population to include pediatric patients 12 years of age and older.
In the Waves study, Stribild was judged to be statistically superior to an atazanavir-based regimen in women.
Results from two studies show that not only do integrase inhibitor-based regimens work well in women, but that they better tolerated than a regimen based on the protease inhibitor atazanavir.
Renal adverse events and fractures proved rare among people taking tenofovir disoproxil fumarate (TDF) as part of a single-tablet regimen in a large U.S. database of insured patients.
A new single-tablet HIV regimen containing tenofovir alafenamide (TAF) offered better bone and kidney safety, according to a study presented at ICAAC/ICC 2015.
We briefly summarize some of the most noteworthy new HIV treatment studies presented at a major research conference that took place this month.
Stribild, compared to Atripla, was efficacious, durable, well-tolerated and safe in treatment-naive Black adults, and may be a viable switch option for virologically suppressed Black patients looking for regimen modification or simplification.
With this approval, each component of the single-tablet regimen Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir) is now green-lighted for use separately in HIV treatment regimens in the U.S.